Dental private equity is investment capital that buys into dental practices, usually through a DSO platform, with the goal of growing the business and selling it later at a higher value. Over the past decade, that capital has reshaped who owns dentistry, and the offers reaching founders are larger and more frequent than ever.
The founders who do well in these conversations understand the buyer's logic before the first call. They know what their practice is worth, what a deal can look like, and what changes once outside capital comes in. The ones who walk in unprepared tend to react to terms instead of shaping them. Strong DSO consulting starts well before a letter of intent.
What Private Equity Wants From Dental Practices
Private equity does not buy a dental practice for its chairs or its patient list alone. It buys a platform it can grow and resell. The return comes from scale, not from the single practice as it stands today.
The model follows a familiar pattern:
- Acquire a platform. A larger, well-run group becomes the base the firm builds on.
- Add on smaller practices. Independent offices get folded in, often at lower multiples than the platform itself.
- Grow earnings. Centralized billing, procurement, and reporting lift margins across every location.
- Sell at a higher value. A bigger, less founder-dependent group commands a stronger multiple than any single office could.
Resale logic is why a credible growth story matters as much as current profit. A practice with clear room to expand is worth more to a buyer underwriting the next five years.
The founders who know their own growth levers walk into these conversations ready to defend their value.
Read: How to Grow Your Dental Practice: 15 Proven Strategies
The Value Drivers PE Buyers Reward
Underwriting comes down to whether the earnings are real, repeatable, and transferable. A few factors carry most of the weight.
- Normalized EBITDA. Buyers adjust earnings to a market-rate compensation and strip out personal or one-time costs, then build the offer on that number.
- Provider durability. Production that walks out the door if one dentist leaves is a risk a buyer prices down.
- Clean financials. Records that hold up under diligence protect your valuation, which is why CFO and financial preparation should be in place early.
- Location and payor mix. Diversified revenue across offices and payers reads as stability instead of concentration risk.
Weak documentation rarely kills a deal outright. It moves value into holdbacks, earnouts, and tighter terms.
Before any of this is tested, it helps to understand your enterprise value first, so the buyer's number meets your own.
How Dental PE Deals Are Structured
A dental PE deal is rarely all cash today. Most combine an upfront payment with equity you carry forward, which shapes both your risk and your upside.
| Deal lever | What it means for you |
| Cash at close | The portion paid upfront, often the majority of the deal |
| Rollover equity | A stake you keep in the larger platform |
| Second bite | A later payout if the platform sells again at a higher value |
| Income scrape | A reduction in your going-forward compensation after close |
Rollover equity is where the biggest gains and risks sit. If the platform grows and sells again in three to seven years, that retained stake can pay a second time. If it underperforms, the same stake can stall.
The compensation change deserves equal attention. Your pay after close often shifts to a productivity or pool model, so ask for a sample calculation before you sign anything. Most deals also commit you to a multi-year employment term, commonly three to five years, so weigh that timeline as carefully as the headline number.
What Changes After Private Equity Comes In
Outside capital reshapes how the practice runs from day one. Clinical care stays with licensed providers, but much of the back office moves to the platform.
The shift is operational, not just financial. Billing, collections, HR, compliance, and procurement often centralize. Systems standardize across locations, reporting cadence tightens, and growth targets arrive with the new partner. Founders who already run on scalable systems integrate faster and protect more of their autonomy through the transition.
A practice built to perform without constant founder oversight carries that strength into a partnership and beyond it.
Read: Dental Office Systems That Scale With Your Practice
Where Tower Leadership Fits in a PE Decision
Most founders meet private equity for the first time across the table from people who do this every day. The asymmetry shows up in the terms.
We prepare founders long before that meeting, connecting valuation, clean financials, leadership depth, and a defensible growth plan into one position. Founder Eric J. Morin, MBA, has advised more than 400 practices past $10M in annual revenue, and our DSO consulting keeps the decision in your hands, whether you partner, sell, or hold.
Book Your Consultation Call With Tower Leadership
A private equity conversation rewards preparation more than reaction. The founders who know their value, their financials, and their goals walk in able to shape the deal instead of accepting it. We built our advisory model on a simple belief, that a practice run as a real enterprise becomes the engine of lasting wealth, and that the founder should stay in control of how that value is realized.
You have already built something worth investing in. Now make sure any deal reflects what it is truly worth.
Book your consultation call to prepare before the first PE conversation, or reach our team directly at (404) 509-0452.
Frequently Asked Questions
What is dental private equity?
Investment firms buying into dental practices, usually through a DSO platform, to grow and resell them at a higher value.
How do private equity firms value a dental practice?
On a multiple of normalized EBITDA, with larger, less founder-dependent groups earning higher multiples.
What is rollover equity?
A stake you keep in the buyer's platform, which can pay a second time if that platform sells again.
Do I keep clinical control after a PE deal?
Clinical decisions stay with licensed providers. The business side shifts toward the platform.
Leave a Reply